Medulloblastoma is the most common malignant brain tumour in children. We can now cure 70 per cent of children affected by it, but the necessarily aggressive treatments can leave them with significant disability. Dr Amin wants to develop a new way of delivering chemotherapy directly to the tumour. Success could ultimately result in the development of a much-needed, less damaging new treatment option for young patients with medulloblastoma.
We’re funding vital research into new ways of treating Medulloblastoma – the most common malignant childhood brain tumour – to improve on the 70 per cent survival rate and reduce the side-effects of treatment.